CD19 expression is maintained after treatment with tafasitamab in patients with DLBCL

During ASH 2024, Dr Johannes Duell from the University of Würzburg (Germany) presented a poster evaluating the CD19 expression before and after treatment with tafasitamab-lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). This analysis demonstrated that the CD19 antigen was maintained on tumor cells after tafasitamab treatment. Furthermore, no somatic mutations in the CD19 gene were detected on end-of-treatment tumor and blood samples collected from patients treated with tafasitamab. As such, these data confirm that CD19 expression is retained after treatment with tafasitamab and underline the potential to treat tafasitamab-exposed R/R DLBCL patients with an alternative anti-CD19 targeting therapy (e.g., CAR-T therapy) in a subsequent treatment line.